Search research articles
Contact Us
Filters
Showing results (221-230 of 2,716) with videos related to
Page
of 272
Sort By:
The Journal of Clinical Psychiatry
|
May 26, 1999
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET
G Remington, S Kapur
Current Opinion in Investigational Drugs (London, England : 2000)
|
January 5, 2002
SB-277011 GlaxoSmithKline
G Remington, S Kapur
Evidence-Based Mental Health
|
August 16, 2002
Review: amisulpride is effective and safe for schizophrenia
Gary Remington, Shitij Kapur
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
November 6, 2001
Electroconvulsive therapy in cases of treatment-resistant psychosis
V Parker, G Remington
Biological Psychiatry
|
December 18, 2001
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient
S Kapur, G Remington
Journal of Clinical Psychopharmacology
|
October 1, 1994
Risperidone and obsessive-compulsive symptoms
G Remington, M Adams
Perception & Psychophysics
|
April 1, 1984
Moving attention: evidence for time-invariant shifts of visual selective attention
R Remington, L Pierce
The American Journal of Psychiatry
|
October 1, 1984
Case report of de Clerembault syndrome, bipolar affective disorder, and response to lithium
G Remington, H Book
Schizophrenia Bulletin
|
July 23, 2008
Negative symptoms in schizophrenia: avolition and Occam's razor
George Foussias, Gary Remington
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
April 8, 2010
Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making
George Foussias, Gary Remington
Page
of 272
Search research articles
Search
Showing results (221-230 of 2,716) with videos related to
Sort By:
Page
of 272
The Journal of Clinical Psychiatry
|
May 26, 1999
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET
G Remington, S Kapur
Current Opinion in Investigational Drugs (London, England : 2000)
|
January 5, 2002
SB-277011 GlaxoSmithKline
G Remington, S Kapur
Evidence-Based Mental Health
|
August 16, 2002
Review: amisulpride is effective and safe for schizophrenia
Gary Remington, Shitij Kapur
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
November 6, 2001
Electroconvulsive therapy in cases of treatment-resistant psychosis
V Parker, G Remington
Biological Psychiatry
|
December 18, 2001
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient
S Kapur, G Remington
Journal of Clinical Psychopharmacology
|
October 1, 1994
Risperidone and obsessive-compulsive symptoms
G Remington, M Adams
Perception & Psychophysics
|
April 1, 1984
Moving attention: evidence for time-invariant shifts of visual selective attention
R Remington, L Pierce
The American Journal of Psychiatry
|
October 1, 1984
Case report of de Clerembault syndrome, bipolar affective disorder, and response to lithium
G Remington, H Book
Schizophrenia Bulletin
|
July 23, 2008
Negative symptoms in schizophrenia: avolition and Occam's razor
George Foussias, Gary Remington
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
April 8, 2010
Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making
George Foussias, Gary Remington
Page
of 272